RE: Up 5% on Nasdaq so far from our cop.5 Mar 2024 17:57
Thanks for the great post infinity888, most useful and clearly points to a huge market and let's not forget this stock was £12 and even brokers have a buy rating on this stock at multiples of the current share price. The more i read the more it appears that AstraZeneca are the ones who are behind the bid imo. Exciting times ahead and we know Astrazeneca have significant market presence and this would probably be an ideal fit. I think buyers will be over this like a rash when the identity of bidder is revealed. There is no stopping other bidders entering the arena either imv. Ive reposted your excellent find below for others to view:
3-5$ target for ADRToday 17:00
Today released
https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-renalytix-ai-amidst-potential-acquisition-and-strong-market-prospects?utm_source=markets.businessinsider.com&utm_medium=referral
BTIG analyst Mark Massaro has reiterated their bullish stance on RNLX stock, giving a Buy rating on March 1.
Mark Massaro has given his Buy rating due to a combination of factors affecting Renalytix AI’s current position and future prospects. The company’s engagement in a formal sale process and the interest it has garnered from a well-capitalized strategic diagnostics company signal potential for acquisition, which is often a positive catalyst for a stock. Additionally, the company’s ongoing discussions to raise either equity or debt from both new and existing investors demonstrate efforts to strengthen its balance sheet. Massaro’s optimism is also based on the company’s solid execution of critical milestones in the past year, despite its relatively low cash reserves.
Massaro’s confidence in the stock is further buoyed by Renalytix AI’s sizable total addressable market, estimated to be over $13 billion, which suggests significant growth potential. Furthermore, the anticipation of increased mergers and acquisitions activity in the sector, as evidenced by recent deals, contributes to the positive outlook for Renalytix AI. The company also has several upcoming catalysts that could drive its value, including a potential acquisition, improvements to its financial position, and advancements in its flagship product, KidneyIntelX. The valuation of the company’s stock at a $3 price target is based on a multiple of future revenue estimates, taking into account an appropriate discount rate and share count.
In another report released on March 1, Stifel Nicolaus also maintained a Buy rating on the stock with a $5.00 price target.
Sign In
Follow the stocks
